Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» non-squamous non-small cell lung cancer
non-squamous non-small cell lung cancer
Good news for Lilly as sintilimab hits the spot in lung cancer again
Pharmaforum
Tue, 10/19/21 - 10:47 am
Eli Lilly
China
Innovent
sintilimab
non-squamous non-small cell lung cancer
non-small cell lung cancer
BeiGene reports positive Phase III interim analysis for lung cancer drug
MedCity News
Wed, 04/15/20 - 10:41 am
BeiGene
clinical trials
immunotherapy
lung cancer
tislelizumab
non-squamous non-small cell lung cancer
FDA Grants Priority Review to Roche's Lung Cancer Drug Tecentriq
Motley Fool
Thu, 02/20/20 - 10:44 am
Roche
FDA
priority review
Tecentriq
non-squamous non-small cell lung cancer
non-small cell lung cancer
Bio-Thera Solutions announces positive top-line results for BAT1706, a proposed biosimilar to Avastin
Pharmaceutical Business Review
Tue, 02/4/20 - 10:05 am
BAT1706
Bio-Thera Solutions
Avastin
Roche
non-squamous non-small cell lung cancer
biosimilars
Mylan up on OK for generic of Lilly’s $2bn cancer drug Alimta
Pharmaforum
Fri, 08/30/19 - 10:48 am
Mylan
Eli Lilly
generics
Alimta
non-squamous non-small cell lung cancer
mesothelioma
Bristol, With Another Lung Cancer Flop, Loses More Ground to Merck
Xconomy
Wed, 07/24/19 - 10:20 pm
Bristol-Myers Squibb
Merck
Keytruda
Opdivo
non-squamous
non-squamous non-small cell lung cancer
FDA gives Merck ‘real-time’ OK for Keytruda, offering a peek at the latest extension of the agency’s data express highway
Endpoints
Tue, 08/21/18 - 10:19 am
Keytruda
Merck
non-squamous non-small cell lung cancer
FDA
US agency to rule on Tecentriq’s most important use
EP Vantage
Wed, 08/15/18 - 11:57 am
Roche
Tecentriq
non-squamous non-small cell lung cancer
FDA
Roche’s Tecentriq scores again on a pivotal frontline lung cancer trial, positioning them against Merck, Bristol-Myers
Endpoints
Tue, 05/29/18 - 08:54 am
Roche
Tecentriq
anti-PD-L1
non-squamous non-small cell lung cancer
Merck
Bristol-Myers Squibb